Health Condition 1: B338- Other specified viral diseases
Conditions
Interventions
Intervention1: tablet Clevira 100 mg.: one tablet twice daily for one week.
Composition:
Erandakarkati (Carica papaya)-Lf. â?? 100mg
Mahanimba (Melia azedarach)-Lf. â?? 100mg
Kalmegh (Andrographis
Sponsors
Apex Laboratories Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Proper written informed consent obtained from the patient before any procedure performed. 2. Males and females between the age of 18-75 years with an oral temperature of more than 38.0°C (100.4°F). with or without associated rash, body pain and joint pain, severe headache especially behind the eyes, nausea and vomiting. 3. Patients having Viral fever with thrombocytopenia, with a platelet count between 80,000 /micro litre to100,000/micro litre. 4. Subjects with stable vitals like pulse and blood pressure 5. Patient should have not participated in any other clinical trial during the past 3 months.
Exclusion criteria
Exclusion criteria: 1. Patients with Dengue hemorrhagic fever grade III and IV 2. Patients with platelet count less than 80,000/micro litre. 3. Pregnant or lactating women 4. Patients who have received blood or blood products transfusion during the current illness 5. Patients with thrombocytopenia Purpura (ITP), Leukemia, Hemophilia 6. Patients who have a serum ALT level 3 times higher than the upper limit of the normal range ( >165 U/L), 7. Impaired renal function with serum creatinine > 1.5 mg/dl (males) and > 1.4 mg/dl (females), 8. Hypersensitivity to any of the components of the formulation, 9. The presence of any other condition that leads the investigator to conclude that the patient is inappropriate for inclusion in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of efficacy parameters namely platelet count, haematocrit, prothrombin time, bleeding time, clotting time â?? baseline & on each day from day 1 to day 3 and on days 5 & 7 (For 24 subjects who suffer from viral fever with thrombocytopenia) Assessment of clinical parameters namely temperature, fever score, arthralgia, myalgia, headache and loss of appetite - baseline and on days 2,4 & 7. (For all 48 subjects)Timepoint: Day 1 to 7 | — |
Secondary
| Measure | Time frame |
|---|---|
| To monitor for any adverse events during the study period and assess the quality of life using a pre-and post-feedback questionnaireTimepoint: day 1 to 7 | — |
Countries
India
Contacts
Public ContactDr Ramesh Kannan
Madras Medical College
Outcome results
None listed